Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Statistical interpretation of the RV144 HIV vaccine efficacy trial in Thailand: a case study for statistical issues in efficacy trials.

Gilbert PB, Berger JO, Stablein D, Becker S, Essex M, Hammer SM, Kim JH, Degruttola VG.

J Infect Dis. 2011 Apr 1;203(7):969-75. doi: 10.1093/infdis/jiq152.

2.

Expected epidemiological impacts of introducing an HIV vaccine in Thailand: a model-based analysis.

Schneider K, Kerr CC, Hoare A, Wilson DP.

Vaccine. 2011 Aug 18;29(36):6086-91. doi: 10.1016/j.vaccine.2011.06.074. Epub 2011 Jul 1.

PMID:
21723902
3.

Evaluating immune correlates in HIV type 1 vaccine efficacy trials: what RV144 may provide.

Rolland M, Gilbert P.

AIDS Res Hum Retroviruses. 2012 Apr;28(4):400-4. doi: 10.1089/AID.2011.0240. Epub 2011 Sep 27.

4.

Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2.

Rolland M, Edlefsen PT, Larsen BB, Tovanabutra S, Sanders-Buell E, Hertz T, deCamp AC, Carrico C, Menis S, Magaret CA, Ahmed H, Juraska M, Chen L, Konopa P, Nariya S, Stoddard JN, Wong K, Zhao H, Deng W, Maust BS, Bose M, Howell S, Bates A, Lazzaro M, O'Sullivan A, Lei E, Bradfield A, Ibitamuno G, Assawadarachai V, O'Connell RJ, deSouza MS, Nitayaphan S, Rerks-Ngarm S, Robb ML, McLellan JS, Georgiev I, Kwong PD, Carlson JM, Michael NL, Schief WR, Gilbert PB, Mullins JI, Kim JH.

Nature. 2012 Oct 18;490(7420):417-20. doi: 10.1038/nature11519. Epub 2012 Sep 10.

5.

The potential impact of a moderately effective HIV vaccine with rapidly waning protection in South Africa and Thailand.

Andersson KM, Stover J.

Vaccine. 2011 Aug 18;29(36):6092-9. doi: 10.1016/j.vaccine.2011.06.060. Epub 2011 Jun 22.

PMID:
21703322
6.

Phase III HIV vaccine trial in Thailand: a step toward a protective vaccine for HIV.

Vaccari M, Poonam P, Franchini G.

Expert Rev Vaccines. 2010 Sep;9(9):997-1005. doi: 10.1586/erv.10.104. Review.

PMID:
20822342
8.

Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand.

Pitisuttithum P, Gilbert P, Gurwith M, Heyward W, Martin M, van Griensven F, Hu D, Tappero JW, Choopanya K; Bangkok Vaccine Evaluation Group.

J Infect Dis. 2006 Dec 15;194(12):1661-71. Epub 2006 Nov 3.

9.

The potential impact of an HIV vaccine with rapidly waning protection on the epidemic in Southern Africa: examining the RV144 trial results.

Andersson KM, Paltiel AD, Owens DK.

Vaccine. 2011 Aug 18;29(36):6107-12. doi: 10.1016/j.vaccine.2011.06.076. Epub 2011 Jul 5.

10.

The cost-effectiveness of a modestly effective HIV vaccine in the United States.

Long EF, Owens DK.

Vaccine. 2011 Aug 18;29(36):6113-24. doi: 10.1016/j.vaccine.2011.04.013. Epub 2011 Apr 19.

11.

Accelerating clinical development of HIV vaccine strategies: methodological challenges and considerations in constructing an optimised multi-arm phase I/II trial design.

Richert L, Doussau A, Lelièvre JD, Arnold V, Rieux V, Bouakane A, Lévy Y, Chêne G, Thiébaut R; Vaccine Research Institute (VRI).

Trials. 2014 Feb 26;15:68. doi: 10.1186/1745-6215-15-68.

12.

Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand.

Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, Premsri N, Namwat C, de Souza M, Adams E, Benenson M, Gurunathan S, Tartaglia J, McNeil JG, Francis DP, Stablein D, Birx DL, Chunsuttiwat S, Khamboonruang C, Thongcharoen P, Robb ML, Michael NL, Kunasol P, Kim JH; MOPH-TAVEG Investigators.

N Engl J Med. 2009 Dec 3;361(23):2209-20. doi: 10.1056/NEJMoa0908492. Epub 2009 Oct 20.

13.

Support for the RV144 HIV vaccine trial.

Belshe R, Franchini G, Girard MP, Gotch F, Kaleebu P, Marthas ML, McChesney MB, McCullough R, Mhalu F, Salmon-Ceron D, Sekaly RP, van Rompay K, Verrier B, Wahren B, Weissenbacher M.

Science. 2004 Jul 9;305(5681):177-80; author reply 177-80. No abstract available.

PMID:
15247455
14.

Human immunodeficiency virus (HIV) immunopathogenesis and vaccine development: a review.

Girard MP, Osmanov S, Assossou OM, Kieny MP.

Vaccine. 2011 Aug 26;29(37):6191-218. doi: 10.1016/j.vaccine.2011.06.085. Epub 2011 Jun 28. Review.

PMID:
21718747
16.

Support for the RV144 HIV vaccine trial.

AIDS Vaccine Advocacy Coalition.

Science. 2004 Jul 9;305(5681):177-80; author reply 177-80. No abstract available.

PMID:
15250069
17.

Lessons from the RV144 Thai phase III HIV-1 vaccine trial and the search for correlates of protection.

Kim JH, Excler JL, Michael NL.

Annu Rev Med. 2015;66:423-37. doi: 10.1146/annurev-med-052912-123749. Epub 2014 Oct 17. Review.

PMID:
25341006
18.

Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144.

Robb ML, Rerks-Ngarm S, Nitayaphan S, Pitisuttithum P, Kaewkungwal J, Kunasol P, Khamboonruang C, Thongcharoen P, Morgan P, Benenson M, Paris RM, Chiu J, Adams E, Francis D, Gurunathan S, Tartaglia J, Gilbert P, Stablein D, Michael NL, Kim JH.

Lancet Infect Dis. 2012 Jul;12(7):531-7. doi: 10.1016/S1473-3099(12)70088-9. Epub 2012 May 30.

19.

International clinical trials of HIV vaccines: I. Phase I trial of an HIV-1 synthetic peptide vaccine in Bangkok, Thailand.

Phanuphak P, Teeratakulpixarn S, Sarangbin S, Nookhai S, Ubolyam S, Sirivichayakul S, Leesavan A, Forrest BD, Hanson CV, Li M, Wang CY, Koff WC.

Asian Pac J Allergy Immunol. 1997 Mar;15(1):41-8.

20.

Sieve analysis in HIV-1 vaccine efficacy trials.

Edlefsen PT, Gilbert PB, Rolland M.

Curr Opin HIV AIDS. 2013 Sep;8(5):432-6. doi: 10.1097/COH.0b013e328362db2b. Review.

Items per page

Supplemental Content

Write to the Help Desk